188 related articles for article (PubMed ID: 23257899)
1. Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.
Palmieri C; Caley MP; Purshouse K; Fonseca AV; Rodriguez-Teja M; Kogianni G; Woodley L; Odendaal J; Elliott K; Waxman J; Sturge J
Br J Cancer; 2013 Jan; 108(1):163-9. PubMed ID: 23257899
[TBL] [Abstract][Full Text] [Related]
2. TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis.
Caley MP; Kogianni G; Adamarek A; Gronau JH; Rodriguez-Teja M; Fonseca AV; Mauri F; Sandison A; Rhim JS; Pchejetski D; Palmieri C; Cobb JP; Waxman J; Sturge J
J Pathol; 2012 Apr; 226(5):775-83. PubMed ID: 22072289
[TBL] [Abstract][Full Text] [Related]
3. The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo.
Wienke D; Davies GC; Johnson DA; Sturge J; Lambros MB; Savage K; Elsheikh SE; Green AR; Ellis IO; Robertson D; Reis-Filho JS; Isacke CM
Cancer Res; 2007 Nov; 67(21):10230-40. PubMed ID: 17974964
[TBL] [Abstract][Full Text] [Related]
4. Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180.
Engelholm LH; Melander MC; Hald A; Persson M; Madsen DH; Jürgensen HJ; Johansson K; Nielsen C; Nørregaard KS; Ingvarsen SZ; Kjaer A; Trovik CS; Laerum OD; Bugge TH; Eide J; Behrendt N
J Pathol; 2016 Jan; 238(1):120-33. PubMed ID: 26466547
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Tumminello FM; Badalamenti G; Incorvaia L; Fulfaro F; D'Amico C; Leto G
Med Oncol; 2009; 26(1):10-5. PubMed ID: 18461289
[TBL] [Abstract][Full Text] [Related]
6. Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression.
Kogianni G; Walker MM; Waxman J; Sturge J
Eur J Cancer; 2009 Mar; 45(4):685-93. PubMed ID: 19112015
[TBL] [Abstract][Full Text] [Related]
7. Endo180 at the cutting edge of bone cancer treatment and beyond.
Sturge J
J Pathol; 2016 Mar; 238(4):485-8. PubMed ID: 26576691
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of uPARAP/Endo180 during culture activation of rat hepatic stellate cells and its presence in hepatic stellate cell lines from different species.
Mousavi SA; Fønhus MS; Berg T
BMC Cell Biol; 2009 May; 10():39. PubMed ID: 19432973
[TBL] [Abstract][Full Text] [Related]
9. The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.
Nielsen CF; van Putten SM; Lund IK; Melander MC; Nørregaard KS; Jürgensen HJ; Reckzeh K; Christensen KR; Ingvarsen SZ; Gårdsvoll H; Jensen KE; Hamerlik P; Engelholm LH; Behrendt N
Oncotarget; 2017 Jul; 8(27):44605-44624. PubMed ID: 28574834
[TBL] [Abstract][Full Text] [Related]
10. The collagen receptor uPARAP/Endo180 in tissue degradation and cancer (Review).
Melander MC; Jürgensen HJ; Madsen DH; Engelholm LH; Behrendt N
Int J Oncol; 2015 Oct; 47(4):1177-88. PubMed ID: 26316068
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
12. The collagen receptor uPARAP/Endo180.
Engelholm LH; Ingvarsen S; Jürgensen HJ; Hillig T; Madsen DH; Nielsen BS; Behrendt N
Front Biosci (Landmark Ed); 2009 Jan; 14(6):2103-14. PubMed ID: 19273187
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of the collagen internalization receptor uPARAP/Endo180 in the stroma of head and neck cancer.
Sulek J; Wagenaar-Miller RA; Shireman J; Molinolo A; Madsen DH; Engelholm LH; Behrendt N; Bugge TH
J Histochem Cytochem; 2007 Apr; 55(4):347-53. PubMed ID: 17189524
[TBL] [Abstract][Full Text] [Related]
15. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
16. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate treatment and radiotherapy in metastatic breast cancer.
Ural AU; Avcu F; Baran Y
Med Oncol; 2008; 25(3):350-5. PubMed ID: 18202925
[TBL] [Abstract][Full Text] [Related]
18. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
Kohno N
Int J Clin Oncol; 2008 Feb; 13(1):18-23. PubMed ID: 18307015
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit.
Bal O; Oksuzoglu B; Dogan M; Durnali A; Uyeturk U; Demirci A; Arslan UY; Ekinci AS; Yildirim N; Alkis N; Kilic S
Ir J Med Sci; 2020 Aug; 189(3):805-810. PubMed ID: 31823174
[TBL] [Abstract][Full Text] [Related]
20. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
